Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test

NCT ID NCT07726134

Disease control Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial compares two common diuretics—furosemide and mannitol—given during kidney transplant surgery to see which better prevents delayed graft function, a condition where the new kidney does not work right away and requires dialysis. The study enrolls adults receiving a deceased-donor kidney transplant. It aims to gather feasibility data and early signals on which drug may reduce complications and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
furosemide or mannitol given intravenously during kidney transplant surgery
What this could lead to
If one drug proves better, it could reduce the need for dialysis after kidney transplant and improve long-term graft survival.
What could go wrong
This is a small pilot study focused on feasibility, not definitive results. The two drugs may turn out to be equally effective, or neither may show a clear advantage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>18 years; 2. Patient is scheduled to receive a deceased-donor kidney transplant (including both NDD and DCD donors) 3. Patient is willing and able to provide written and informed consent, or a substitute decision maker (SDM) is available to sign on the patient's behalf Exclusion Criteria: 1. Patient is receiving another organ at the time of their kidney transplant (e.g., simultaneous kidney-pancreas or kidney-liver) 2. Known allergy or contraindication to mannitol or furosemide 3. Inability to provide informed consent 4. Pediatric recipients (\<18 years of age) 5. Previously enrolled in this clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Delayed graft function are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Delayed Graft Function end stage renal failure ischemia reperfusion injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Delayed graft function Kidney transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • London Health Sciences Centre

    London, Ontario, n6a 5a5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.